Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.5K
Mitochondrial Membranes01:45

Mitochondrial Membranes

17.7K
A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
17.7K
Mitochondrial Precursor Proteins01:39

Mitochondrial Precursor Proteins

3.9K
Mitochondrial precursors are partially unfolded or loosely folded polypeptide chains. Newly synthesized precursors are inhibited from spontaneously folding into their native conformation by the cytosolic chaperones, heat shock proteins 70 (Hsp70), and mitochondrial import stimulation factors (MSFs). Precursors bound to MSFs are guided to the TOM70-TOM37 receptors, while precursors bound to Hsp70  chaperones are targetted to TOM20-TOM22 receptor complexes.
Most of the mitochondrial...
3.9K
Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

10.0K
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
10.0K
Mitochondria01:37

Mitochondria

21.2K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
21.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A changed landscape: five-year retrospective on the paradigm shift in genetic testing practices for ALS in Canada.

European journal of human genetics : EJHG·2026
Same author

The m.14484T>C MT-ND6 Mutation Presenting with a Hereditary Spastic-Paraparesis Phenotype.

Movement disorders clinical practice·2026
Same author

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Same author

The Oral Microbiome in Amyotrophic Lateral Sclerosis Shows Differentially Abundant Organisms in Limb Versus Bulbar Onset Disease: A Binational Study.

Journal of clinical neurology (Seoul, Korea)·2026
Same author

Counting the Cost: The Hidden Financial Realities of Neuromuscular Disease Through Patient and Family Perspectives.

Health expectations : an international journal of public participation in health care and health policy·2025
Same author

Comprehensive analysis platform to understand, remedy, and eliminate amyotrophic lateral sclerosis (CAPTURE ALS): Study protocol for a Canadian multicenter, multimodal, longitudinal observational study.

PloS one·2025

Related Experiment Video

Updated: Mar 21, 2026

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
08:56

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes

Published on: October 10, 2025

835

Emerging therapies for mitochondrial disorders.

Helen Nightingale1, Gerald Pfeffer2, David Bargiela1

  • 1Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK.

Brain : a Journal of Neurology
|May 19, 2016
PubMed
Summary
This summary is machine-generated.

Mitochondrial disorders, caused by DNA mutations, lack effective treatments despite decades of supplements. Promising new preclinical strategies offer hope for breakthroughs in treating these debilitating conditions.

Keywords:
gene therapiesmitochondrial disorderspharmaceuticalsproteintreatment

More Related Videos

Generation of Human Brain Organoids for Mitochondrial Disease Modeling
08:09

Generation of Human Brain Organoids for Mitochondrial Disease Modeling

Published on: June 21, 2021

6.9K
An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model
06:05

An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model

Published on: March 9, 2022

4.5K

Related Experiment Videos

Last Updated: Mar 21, 2026

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
08:56

Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes

Published on: October 10, 2025

835
Generation of Human Brain Organoids for Mitochondrial Disease Modeling
08:09

Generation of Human Brain Organoids for Mitochondrial Disease Modeling

Published on: June 21, 2021

6.9K
An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model
06:05

An In Vitro Approach to Study Mitochondrial Dysfunction: A Cybrid Model

Published on: March 9, 2022

4.5K

Area of Science:

  • Genetics and Molecular Biology
  • Neuroscience
  • Biochemistry

Background:

  • Mitochondrial disorders stem from DNA mutations, impacting multiple organs, notably the nervous system.
  • Current treatments, including vitamins and supplements, have shown no proven benefit for over 50 years.
  • A significant unmet need exists for novel therapeutic strategies.

Purpose of the Study:

  • To critically evaluate promising preclinical developments for mitochondrial disorders.
  • To focus on novel strategies for diseases caused by mitochondrial DNA mutations.
  • To assess the clinical potential of emerging molecular and cellular therapies.

Main Methods:

  • Review of preclinical research on novel therapeutic strategies.
  • Emphasis on in vitro and animal models.
  • Analysis of data from deep phenotyping in patient cohorts.

Main Results:

  • Many proposed strategies show promise in vitro, but clinical efficacy remains uncertain.
  • Preclinical developments are advancing with new models and patient data.
  • Growing pharmaceutical interest indicates a potential shift in treatment development.

Conclusions:

  • Existing treatments for mitochondrial disorders are ineffective.
  • New preclinical strategies are emerging, with a focus on mitochondrial DNA mutation-related diseases.
  • The field is nearing a breakthrough due to improved models, patient data, and industry investment.